Skip to content

Short Integrative And Neurocognitive Therapy For Young Adults With Borderline Personality Disorder

Short Integrative And Neurocognitive Therapy For Young Adults With Borderline Personality Disorder: a Study Model of Impulsivity Management

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05913544
Acronym
SINTYA
Enrollment
74
Registered
2023-06-22
Start date
2023-11-08
Completion date
2026-09-30
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borderline Personality Disorder

Brief summary

Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).

Interventions

OTHERSINTYA

10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
16 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale. * High BPD severity level: ZAN-BPD (score ≥ 18/36). * Understand, write and read French. * Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations. * Have signed the informed consent. * For minor patients, have signed the parental consent by at least one holder of parental authority.

Exclusion criteria

* Refusal to participate. * Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance. * Intelligence quotient \< 70. * Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7). * Previous or current participation in specific psychotherapy for BPD. * Subject deprived of liberty (by judicial or administrative decision) and/or protected by law. * Inclusion in another study including psychotherapy for the duration of the study. * Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study. * Subject in period of exclusion from another research protocol.

Design outcomes

Primary

MeasureTime frameDescription
Variation in explicit impulsivity between groupsBaselineUPPS-S (Impulsive Behavior Scale Short version score)

Secondary

MeasureTime frameDescription
Variation in explicit impulsivity between groupsMonth 7UPPS-S (Impulsive Behavior Scale Short version score)
Variation in impulsiveness between groupsBaselineBarratt Impulsiveness Scale (BIS-11) (score out of 120)
BPD severity level between groupsBaselineZanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)
Emotional regulation capacities between groupsBaselineDifficulties in Emotion Regulation Scale (DERS-18)
Dissociative symptoms between groupsBaselineDissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder
Aggression between groupsBaselineAggression Questionnaire (AQ-12)
Ruminations between groupsBaselineRumination Reflection Questionnaire (RRQ)
Psychosocial functioning between groupsBaselineFunctional Assessment Staging Tool (FAST)
Number of impulsive behaviors between groupsBaselineNumber of impulsive behaviors (food, motor vehicles, sexual, drug-related)
Level of suicide risk between groupsBaselineColumbia-Suicide Severity Rating Scale (C-SSRS)
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups12 Months prior to inclusionInformation taken from patient medical file
Implicit impulsivity between groupsBaselineContinuous Performance Test (CPT)
Neurocognitive evaluation of implicit impulsivity between groupsBaselineEmotional Stroop (SE) customized to the study
Risk taking between groupsBaselineBalloon Analogue Risk Task (BART)
Decision making under risk conditions between groupsBaselineGame Dice Task (GDT)
Number of self-destructive behaviors between groupsBaselineNumber of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Countries

France

Contacts

Primary ContactClémentine Estric
clementine.estric@chu-nimes.fr04 66 68 34 26

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026